A&M Labor fuer Analytik und Metabolismusforschung Service
A&M Labor fuer Analytik und Metabolismusforschung Service is recorded as a service provider in 6 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 6 of 6 trials · Latest update first
[22961] A placebo-controlled, parallel-group, double blind, randomized, multi-cohort Phase 2 study to investigate efficacy, safety, tolerability, pharmacodynamics and pharmacokinetics of BAY 3670549 in adult participants with atrial fibrillation.
Sponsor Bayer AG
- Start (EU)
- Latest update
- Estimated end
An Open-label study of patients with primary sclerosing cholangitis (PSC) treated with norucholic acid tablets
Sponsor Dr. Falk Pharma GmbH
- Start (EU)
- Latest update
- Estimated end
PHOENIX - ECP: A Phase 2, Randomized, Controlled, Open-label, Multicenter Study to Evaluate the Efficacy and Safety/Tolerability of Extracorporeal Photopheresis (ECP) Versus Best Available Therapy (BAT) for the Treatment of Immune-related Colitis and/or Hepatitis with Inadequate Response to Corticosteroids in Participants with Unresectable or Metastatic Melanoma Treated with Immune Checkpoint Inhibitors (ICI)
Sponsor Therakos Europe Limited
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Phase II, Double-Blind, Randomised, Placebo-Controlled Trial to Evaluate the Efficacy and Tolerability of ZED1227 in Celiac Disease Subjects Experiencing Symptoms Despite Gluten-Free Diet
Sponsor Dr. Falk Pharma GmbH
- Start (EU)
- Latest update
- Estimated end
(21839) A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in participants with chronic kidney disease and type 2 diabetes.
Sponsor Bayer AG
- Start (EU)
- Latest update
- Estimated end
(22040 ALPINE 1) A Phase 2b dose-finding, randomized, placebo-controlled, double-blind study to evaluate efficacy and safety of BAY 3283142 on top of standard of care in reducing albuminuria in patients with chronic kidney disease
Sponsor Bayer AG
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for A&M Labor fuer Analytik und Metabolismusforschung Service?
The 2026-10-09 snapshot links A&M Labor fuer Analytik und Metabolismusforschung Service to 6 distinct CTIS trials. Recorded services include Laboratory services, Analysis of biomarker plasma analyte, archiving of blood samples for future trial-related scientific investigation, pharmacokinetics, among 5 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for A&M Labor fuer Analytik und Metabolismusforschung Service?
The most frequently recorded therapeutic areas are Gastroenterology, Hepatology, Immunology, Cardiology. Recorded phases include Phase 2, Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to A&M Labor fuer Analytik und Metabolismusforschung Service conducted?
The linked trials record locations in 20 countries, including Germany, Italy, Belgium, Spain, Netherlands. These are trial locations, not confirmed office locations or countries where A&M Labor fuer Analytik und Metabolismusforschung Service delivered services.
What can this page tell me about A&M Labor fuer Analytik und Metabolismusforschung Service's trial experience?
Browse 6 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under A&M Labor fuer Analytik und Metabolismusforschung Service. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- A&M Labor fuer Analytik und Metabolismusforschung Service GmbH